Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, S Orsola-Malpighi University Hospital, Bologna 40138, Italy. Electronic address: alessandro.rizzo11@studio.unibo.it.
² Department of Experimental, Diagnostic and Specialty Medicine, S Orsola-Malpighi University Hospital, Bologna 40138, Italy.

Comment

Alessandro Rizzo et al. Lancet Oncol. 2022 Jan.

. 2022 Jan;23(1):e11.

doi: 10.1016/S1470-2045(21)00664-1.

¹ Department of Experimental, Diagnostic and Specialty Medicine, S Orsola-Malpighi University Hospital, Bologna 40138, Italy. Electronic address: alessandro.rizzo11@studio.unibo.it.
² Department of Experimental, Diagnostic and Specialty Medicine, S Orsola-Malpighi University Hospital, Bologna 40138, Italy.

No abstract available

Conflict of interest statement

We declare no competing interests.

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, Kang BW, Ryu H, Lee JS, Kim KW, Abou-Alfa GK, Ryoo BY. Yoo C, et al. Lancet Oncol. 2021 Nov;22(11):1560-1572. doi: 10.1016/S1470-2045(21)00486-1. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656226 Clinical Trial.
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply.
Yoo C; NIFTY trial investigators. Yoo C, et al. Lancet Oncol. 2022 Jan;23(1):e12. doi: 10.1016/S1470-2045(21)00712-9. Lancet Oncol. 2022. PMID: 34973222 No abstract available.